Edward Tenthoff

Jay Olson

Reni Benjamin

Jiale Song

Roger Song

- Sutro Biopharma, Inc. announced an **operational restructuring** to prioritize its three ADC programs and research and development collaborations.  **[1382101_0001193125-25-223434_stro-ex99_1.htm:0]** 
- This restructuring is expected to **extend the company's cash runway into at least mid-2027**.  **[1382101_0001193125-25-223434_stro-ex99_1.htm:0]** **[1382101_0001193125-25-223434_stro-20250929.htm:1]** 
- The plan includes a **workforce reduction of approximately one-third** of employees.  **[1382101_0001193125-25-223434_stro-ex99_1.htm:0]** **[1382101_0001193125-25-223434_stro-20250929.htm:1]** 
- Total estimated costs for the restructuring are between **$4.1 million and $4.3 million**, with the majority expected to be paid in **Q4 2025**.  **[1382101_0001193125-25-223434_stro-20250929.htm:1]** 
- The company anticipates initial clinical data from its STRO-004 program in **2026**.  **[1382101_0001193125-25-223434_stro-ex99_1.htm:0]** **[1382101_0001193125-25-223434_stro-20250929.htm:1]**

Sutro Biopharma Announces Operational Restructuring

- Sutro Biopharma announced an organizational restructuring to prioritize its three antibody drug conjugate (ADC) programs and research and development collaborations.  **[1382101_78b3c2d309aa42709aaaffcf0ef7e199_0]** 
- This restructuring, along with expected near-term milestone payments, is anticipated to extend the company's cash runway into at least **mid-2027**.  **[1382101_78b3c2d309aa42709aaaffcf0ef7e199_0]** 
- The restructuring will result in a planned **workforce reduction of approximately one-third of employees**.  **[1382101_78b3c2d309aa42709aaaffcf0ef7e199_0]** 
- The company expects to announce initial clinical data from STRO-004 in **2026** and initiate clinical studies for at least one additional ADC program.  **[1382101_78b3c2d309aa42709aaaffcf0ef7e199_0]**

SUTRO BIOPHARMA (STRO)